Frequency Therapeutics is working on a progenitor cell-related treatment for hearing loss based on research conducted at MIT and Harvard Medical School.
Frequency Therapeutics, a US-based creator of progenitor cell-related medicines, closed a $32m series A round on Wednesday that included life sciences real estate trust Alexandria Real Estate Equities.
Investment manager CoBro Ventures led the round, which also featured Morningside Ventures, Emigrant Capital, Korean Investment Partnership and undisclosed investors from the US and overseas.
Founded in 2015, Frequency is developing small-molecule drugs that will restore healthy tissue by activating progenitor cells. It is currently focusing on therapies that will treat noise-induced…